Increlex therapy is highly targeted, addressing growth failure in specific pediatric patients (aged two years and older) whose condition stems from a critical hormonal deficit.

This medication is commonly used for managing the long-term treatment of growth failure in children diagnosed with Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD), a condition characterized by symptoms related to systemic imbalance, where supportive management is appropriate. This severe condition is defined by extremely low levels of IGF-1 and markedly short stature. The medication is relevant in conditions characterized by periods of heightened symptoms such as Severe Primary IGF-1 Deficiency and other conditions involving episodic or fluctuating manifestations of growth hormone resistance.

“The medication is applied in addressing the progressive linear growth failure in patients who require additional symptomatic support to sustain development.”

In clinical scenarios, the treatment is applied in addressing the progressive linear growth failure, helping the body address symptoms related to systemic imbalance. This supports the patient during difficult episodes of slow growth, which may assist with managing the symptoms that interfere with daily functioning. This assists with maintaining functional stability and supports the patient during difficult episodes by easing discomfort associated with these symptoms.

Quick Fact: Support for Short Stature
Supports the patient during recurrent or episodic manifestations of growth failure by providing assistance in addressing symptoms related to systemic imbalance.

Increlex is approved for use in pediatric patients aged 2 years and older with Severe Primary IGF-1 Deficiency (SPIGFD) or with Growth Hormone (GH) gene deletion who have neutralizing antibodies to GH. Eligibility is restricted to patients who still have open epiphyses (unfused growth plates), as the medication is not for use in growth promotion once plates have closed.

---

Contraindicated Populations

Increlex is contraindicated (must not be used) in patients with the following conditions, as stated in official labeling:

Condition
Active or suspected malignant neoplasia (cancer), or a history of malignancy.
Closed epiphyses (fused growth plates).
Known hypersensitivity to mecasermin or any of its excipients.

---

Specific Population Restrictions

Population Group	Regulatory Status
Infants/Neonates	Contraindicated due to the presence of the preservative benzyl alcohol.
Children below 2 years	Safety and effectiveness have not been established; not recommended.
Secondary IGF-1 Deficiency	Not intended for use (e.g., GH deficiency, malnutrition).
Renal/Hepatic Impairment	Limited data are available; requires individualized consideration.
Pregnancy/Lactation	Should not be used unless clearly necessary during pregnancy; not recommended while breastfeeding.

Official Regulatory Information for Mecasermin (Increlex)

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Antidiabetic Agents (including insulin and oral hypoglycemic drugs)
Specific interacting medicines (if explicitly listed)	Insulin
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction (additive effects on glucose metabolism)
Timing-based interaction rules (if applicable)	Administration timing relative to food is mandatory.
Population-specific interaction notes (if applicable)	None explicitly stated regarding increased interaction severity with co-administered agents.
Interaction-related restrictions	Required co-administration management rule: Must be administered within 20 minutes of a meal or snack.

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Use-with-caution (due to significant risk of additive hypoglycemic effects)
Regulatory basis (EMA / FDA / etc.)	FDA Prescribing Information and EMA European Public Assessment Report
Interaction-context constraints (as defined in official documents)	Drug-food interaction (timing rule) and Drug-drug interaction (pharmacodynamic risk)

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Insulin and other Antidiabetic Agents, such as oral hypoglycemic drugs, is officially recognized to result in a potent additive hypoglycemic effect. This is a pharmacodynamic interaction where both substances independently contribute to lowering blood glucose.
• Mecasermin is required to be administered shortly before or shortly after, specifically within 20 minutes, of a meal or snack. This strict administration rule is documented to manage the drug’s glucose-lowering action.
• No specific medicinal products or product classes are formally listed in regulatory documents as absolute contraindicated combinations with Mecasermin.
• No clinically significant pharmacokinetic interactions involving the Cytochrome P450 (CYP) enzyme system or drug transporters are documented in official regulatory sources.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile for Mecasermin is primarily defined by a significant, documented pharmacodynamic interaction with antidiabetic agents, which carries a risk of additive effects. This risk dictates the mandatory drug-food timing rule for administration, a key regulatory constraint. Regulatory documents confirm the absence of specific warnings regarding common pharmacokinetic interactions, thereby focusing the entire interaction structure on glucose homeostasis management.

Binding and Activation of the IGF-1 Receptor

Mecasermin is a recombinant human Insulin-like Growth Factor-1 (IGF-1) that substitutes for the endogenous ligand. Its pharmacodynamic mechanism involves binding to and acting as an agonist for the high-affinity Type 1 IGF Receptor (IGF-1R), a transmembrane tyrosine kinase receptor. This ligand-receptor interaction initiates the signal transduction event.

The binding of mecasermin to IGF-1R leads to autophosphorylation of the receptor’s intracellular domain. This phosphorylation event triggers complex intracellular signaling pathways, notably the PI3K/Akt pathway and the MAPK pathway, which mediate the full spectrum of IGF-1 activity. The resulting cascade activation drives cellular processes such as proliferation, differentiation, and the inhibition of apoptosis in target tissues, thereby modulating metabolic homeostasis and cellular dynamics.

Administration Overview

Increlex is administered via subcutaneous injection. This method involves delivering the medication into the fatty tissue layer just beneath the skin. Common injection sites include the upper arms, thighs, buttocks, or abdomen.

Injection Technique

To ensure the medication is absorbed correctly and to minimize discomfort, it is important to follow a consistent routine. The injection site should be rotated for every dose. This means a different anatomical area should be chosen for each administration to prevent the development of localized skin changes, such as lipohypertrophy, which is a buildup of fatty tissue that can affect medication absorption.

Preparation and Handling

The solution should be inspected visually before use. It must be clear and colorless. If the liquid is cloudy, contains particles, or appears discolored, it should not be used.

Timing and Diet

This medication is typically administered shortly before or shortly after a meal or snack. The presence of food in the system is an important factor in how the body manages the effects of the treatment. If a meal is missed, the corresponding dose is generally not administered, as the medication requires nutritional intake to maintain balanced blood sugar levels.

Increlex: Recent Clinical Evidence

---

Evidence for Growth Failure in Severe Primary IGF-1 Deficiency (SPIGFD)

Research on Increlex was initially conducted to explore its role in conditions characterized by functional limitations, specifically Severe Primary IGF-1 Deficiency (SPIGFD) in children and adolescents. The research included a small, randomized, double-blind, placebo-controlled trial, which provides a comparative structure for examining short-term changes. These were complemented by several long-term, uncontrolled, open-label studies. The research focused on measuring outcomes related to physical growth, such as the speed of growth (Height Velocity) and the overall change in stature (Height Standard Deviation Score). Studies reported measurements of physical growth metrics during the study period, including tracking changes in serum IGF-1 levels. Because this is a very rare condition, sample sizes were modest, meaning research does not determine whether an individual will respond similarly.

---

Long-Term Observational Studies and Follow-Up

After the initial comparative trials, participants were often moved into long-term observational settings and registries. These studies observed responses over defined time intervals, and research examined outcomes related to Near-Adult Height (skeletal maturity). This long-term research describes patterns observed in the studies related to the progression of physical development. However, follow-up durations were limited for some participants, and comparative evidence is lacking, as much of the extended duration data comes from open-label designs. There is limited information for long-term outcomes beyond physical height.

---

Evidence Landscape in Specific Populations

Research also explored a specific group of children who have a GH gene deletion and developed antibodies that block growth hormone. These studies examined outcomes related to systemic or functional imbalance in this specific group. The research for this specific scenario contributes to the broader evidence landscape describing short-term changes in this specific genetic and immunological profile. Since the condition is exceptionally rare, the research provides context but not individual predictions, and data for certain groups remain insufficient.

---

What Research Gaps and Uncertainties Remain

Evidence highlights what is known—and what is still uncertain— about the condition itself. Certainty remains low for many aspects beyond the core growth measurements. Specifically, long-term effects are not fully established, and there is limited information for long-term outcomes such as detailed data on bone density or patient-reported outcomes describing perceived discomfort and quality of life. Studies contribute to the broader evidence landscape describing short-term changes, but the data on durability and consistency of measured changes over years are limited, and subgroup findings are uncertain.

Common questions about Increlex (FAQ)

Q: What is the main difference between Increlex and traditional growth hormone (GH) therapy?

Official product information describes Increlex as a direct replacement for Insulin-like Growth Factor-1 (IGF-1), not a conventional growth hormone (GH) substitute. It is prescribed for children with a specific type of growth failure where their bodies do not respond adequately to naturally produced growth hormone. This mechanism reflects its intended function as a replacement for the missing IGF-1 signal.

Q: Why does Increlex sometimes cause low blood sugar (hypoglycemia) in children?

The active ingredient in Increlex, mecasermin, is classified as an Insulin-like Growth Factor-1. This means its fundamental action in the body includes an insulin-like effect on blood glucose. This mechanism is why the medication can sometimes cause hypoglycemia (low blood sugar) in patients.

Q: Can Increlex affect the tonsils or cause breathing issues like sleep apnea?

Official safety documents state that tonsillar and adenoidal hypertrophy (enlargement of the tonsils and adenoids) is a common adverse reaction. This enlargement may be associated with secondary complications such as snoring and sleep apnea. Because of this, regular monitoring by a specialized physician is a necessary part of the treatment.

Q: Can a child with mild diabetes be treated with Increlex?

Because Increlex has an additive effect on lowering blood glucose, co-administration with other antidiabetic agents, such as insulin, is a documented interaction. Official information indicates that co-administration may require adjustment of the antidiabetic agent dose by the prescribing physician.

Q: What should be done if a meal is missed and the child has already had their Increlex injection?

The official administration protocol requires the dose to be withheld if the patient is unable to eat. If an injection was administered and the meal is then missed, immediate guidance from a healthcare provider on managing the risk of low blood sugar is necessary. This is why the drug has a strict administration timing rule.

Q: Is the increase in growth rate maintained over many years of treatment?

Studies have examined the effect of the medication over several years. Evidence indicates that while the speed of growth (height velocity) typically increases significantly during the initial year of treatment, studies describe a pattern where the initial significant increase in growth rate tends to stabilize at a slower pace in later years of therapy.

Q: What criteria are used by doctors to decide when to discontinue Increlex therapy?

According to official regulatory criteria, treatment must be discontinued if the patient develops an active malignant neoplasia (cancer) or if they develop closed epiphyses (fused growth plates). Additionally, discontinuation can also be considered if the measured growth velocity does not meet established clinical thresholds.

Q: Why is the dosing based on a child's body weight?

The dosage is calculated based on the child's body weight (mathrmmg/mathrmkg) to help ensure the dose is accurately individualized. This method is used to standardize the dose, which is then managed based on the patient's individual tolerability and weight changes.

Q: Can children with kidney or liver problems still be treated with Increlex?

Regulatory documents note that there is limited data available regarding how mecasermin is processed in children with existing kidney (renal) or liver (hepatic) impairment. Therefore, any decision regarding dosing in these situations involves careful individualized assessment and specialized medical supervision.

Q: Does the treatment require continuous monitoring of blood sugar levels?

Yes, because of the risk of low blood sugar, glucose monitoring is officially recommended. Monitoring is typically done at the start of treatment and until the treatment plan, including the dose, is fully established. It is also recommended whenever the patient shows frequent signs of hypoglycemia or if otherwise medically indicated.

Q: What are the specific signs of low blood sugar that parents should watch for after an injection?

The signs of hypoglycemia (low blood sugar) may include feelings of dizziness, tiredness, or restlessness. Other physical signs to watch for include sudden hunger, sweating, nausea, and a fast or irregular heartbeat. If severe symptoms occur, official guidance states that immediate medical assistance should be sought.

Q: What does it mean that the bone growth plates must be 'open' to use Increlex?

The requirement for open growth plates (epiphyses) means the child must still be in a phase of active, physical growth. The medication is officially contraindicated (not allowed) once a child's growth plates have closed or fused, which occurs when the body reaches final adult height.

Q: Does Increlex have any known interactions with common over-the-counter medications?

Official product information advises patients to inform their healthcare professional of all medicines being taken, including any prescription or nonprescription (over-the-counter) products. Precautions may be necessary, and any potential co-administration should be reviewed with the prescribing physician.

Q: Are there specific types of steroid medicines that are known to interact with Increlex?

The medication is not indicated for use in types of growth failure caused by other factors, specifically mentioning that growth failure due to chronic treatment with pharmacologic doses of anti-inflammatory steroids is an exclusion. This means chronic steroid use is a factor that should be included in the physician's evaluation.

Q: How quickly can an increase in growth rate be expected after starting Increlex?

Clinical studies examined the speed of growth, known as height velocity. Evidence indicates that, on average, the mean height velocity achieved by patients nearly tripled over the pre-treatment baseline rate during the first year of therapy.

Q: Is it safe to travel on an airplane with Increlex, and how should it be kept cold?

Regulatory storage rules require the medication to be continuously refrigerated between 2 C and 8 C (36 F and 46 F) and state that it must not be frozen. When traveling, the use of appropriate containers is required to ensure these temperature constraints are strictly maintained throughout the journey.

Q: Why is it forbidden to double a missed dose?

The official administration rules state that a dose should never be increased to compensate for a missed dose. Doses higher than the amount prescribed increase the potential risk for a serious hypoglycemic effect (severe low blood sugar).

Q: Does taking Increlex increase the risk of eye problems, such as retinal swelling?

Official warnings include a risk of Intracranial Hypertension (IH), which may cause changes in vision and is associated with swelling of the optic nerve (papilledema). Due to this potential risk, a specialized physical examination of the eye (funduscopic examination) is officially recommended as part of the periodic monitoring.

Q: What are the required monitoring tests (bloodwork, X-rays) for children on Increlex?

Regulatory documents specify several areas for monitoring. This includes glucose monitoring and a specialized funduscopic examination to check for signs of Intracranial Hypertension. Regular examinations for lymphoid tissue enlargement and evaluation for Slipped Capital Femoral Epiphysis (SCFE) are also required. An echocardiogram may also be recommended before and after treatment.

Q: Is it possible to develop a resistance or stop responding to Increlex over time?

Studies have considered the possibility of a patient stopping response to the medication. Official information indicates that patients who fail to show a growth response may be experiencing an antibody response to the injected IGF-1 protein. In such cases, physicians may consider antibody testing to investigate the lack of expected effect.

Q: Can a child be treated with both Increlex and other treatments for a non-growth-related condition?

The official product information focuses primarily on interactions with antidiabetic agents. For non-growth-related conditions, co-administration of other treatments is generally considered permissible, but the prescribing physician must assess potential risks on an individualized basis.

Q: Is there a chance the face or soft tissues may thicken or swell during treatment?

Yes, official adverse reaction reports include the thickening of facial skin as a possible side effect. Localized swelling at the injection site (known as injection site hypertrophy) is also a common occurrence.

How to Store and Dispose of Increlex (Mecasermin)

Official regulatory guidelines strictly define the storage, handling, and disposal of Increlex to maintain product integrity and safety.

Condition	Requirement	Constraint
Storage Temperature	Refrigerate between 2 C and 8 C (36 F and 46 F).	Do not freeze.
In-Use Stability	Discard vial 30 days after the first use (first puncture).	The solution must be clear; do not use if cloudy or contains particles.
Handling/Protection	Store in the original outer carton to protect from light.	Keep medicine and all used supplies away from children.
Disposal of Sharps	Used needles and syringes must be placed immediately in a dedicated, puncture-resistant sharps disposal container.	Do not put loose needles/syringes or the sharps container in household trash or recycling.

All unused or expired product and used sharps must be managed according to these labeled requirements. Consult local guidelines for approved sharps disposal locations.